Study aimed to characterise treatment and outcomes for patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC) within a large regional cancer centre, as a benchmark for evaluating real-world impact of novel therapies. | Systemic treatment of hormone receptor positive human epidermal growth factor 2 negative metastatic breast cancer Retrospective analysis from Leeds Cancer Centre